MedTrace Logo

Combined Radiotherapy and Sorafenib in Patients With Hepatoma

NCT01319942 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2011-03-22

No results posted yet for this study

Summary

This study aims to test the efficacy of combined radiotherapy and sorafenib in patients with locally advanced hepatocellular carcinoma.

Conditions

Interventions

OTHER

Radiotherapy combined with sorafenib

Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Shang-Wen Chen, MD · Department of Radiation Oncology, China Medical University Hospital

Eligibility

Min Age
20 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-06-30
Completion
2013-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01319942 on ClinicalTrials.gov